SCHEMBL14040573

SCHEMBL14040573

CCN(C)CCOC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
TSHR P16473 1/20 0.46
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CHRM5 P08912 3/20 0.41
CHRM1 P11229 3/20 0.41
CHRM3 P20309 3/20 0.41
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PGR P06401 1/20 0.41
HTR1A P08908 1/20 0.41
TBXA2R P21731 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA10 Q9GZZ6 1/20 0.41
CHRNA9 Q9UGM1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65062 0.88 ALDH1A1 (0.48) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL15368917 0.85 ALDH1A1 (0.54) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL11981282 0.84 ALDH1A1 (0.52) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL17401255 0.84 ALDH1A1 (0.44) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL16845050 0.82 CHRM2 (0.40) ALDH1A1LMNACHRM5CHRM1CHRM3
SCHEMBL27695724 0.81 ALDH1A1 (0.46) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL15685108 0.81 ALDH1A1 (0.59) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL12437964 0.80 DNM1 (0.47) ALDH1A1CHRM5CHRM1CHRM3CHRM2
SCHEMBL18211575 0.80 PIK3CD (0.43) ALDH1A1TSHRLMNAHSD17B10CHRM5
SCHEMBL18827219 0.80 ALDH1A1 (0.41) ALDH1A1TSHRLMNAHSD17B10CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-10978216-B2 Conductive film and method for producing the same SUMITOMO RIKO COMPANY LIMITED (JP) 2021-04-13 US disclosed
US-20150104502-A1 BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF LAUREN SCIENCES LLC 2015-04-16 US disclosed
EP-1411940-B1 BRIDGED PIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS MERCK & CO INC (US) 2008-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150104502-A1 BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF LGALS1, BOLA2; BOLA2B, LGALS2 ALDH1A1 170/4885TSHR 4758/4885LMNA 4067/4885
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 ALDH1A1 4344/4885TSHR 2238/4885LMNA 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.